Multiple myeloma is a type of blood cancer that affects the plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow, crowding out the normal plasma cells that help fight infections. These malignant plasma cells then produce abnormal proteins (m protein), which may cause tumors, damage the kidneys, and impair immune system function.
Multiple myeloma is the second most common blood cancer, and although it is considered incurable, it is very much a treatable disease thanks to recent advancements in cancer research. Historically, there was little hope for multiple myeloma patients, because multiple myeloma treatment options were incredibly limited. Advances in the space have revolutionized the way multiple myeloma is treated, substantially improving the life expectancy of multiple myeloma patients.
CURE Media Group’s flagship product, CURE magazine, is the indispensable guide to every stage of the cancer experience. With nearly 1 million readers, CURE is the largest consumer publication in the United States focused entirely on cancer, with broad distribution to cancer patients, cancer centers and advocacy groups. CURE Media Group’s offerings also include its online resource, curetoday.com; live meetings; a resource guide for the newly diagnosed; and the Extraordinary Healer™ national nursing award. CURE Media Group combines science and humanity to make cancer understandable.
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. With a focus on delivering transformational therapies for cancer patients GSK’s pipeline includes immuno-oncology, cell therapy, and epigenetics. Our goal is to achieve a sustainable flow of new treatments for cancer patients based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, multi-specific molecules, adjuvants and cells, either alone or in combination. Company values are Patient focus, Transparency, Respect and Integrity.
Bristol Myers Squibb is inspired by a single vision–transforming patients' lives through science. The goal of the company's cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine, and through innovative digital platforms, are turning data into insights that sharpen their focus. Deep scientific expertise, cutting-edge capabilities and discovery platforms enable the company to look at cancer from every angle. Cancer can have a relentless grasp on many parts of a patient's life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship. Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.
Sanofi Genzyme is the specialty care global business unit of Sanofi. We strive to help people with complex conditions that may be difficult to treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com.